Skip to main content

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age

Completed · Phase 3 · NCT05330975

Conditions: Respiratory Syncytial Virus

At a glance

Research payments reported, 2025
$2.0M
U.S. investigators named
38
Sites paid
22
Planned or actual enrollment
3,317

About the trial

Sponsor
ModernaTX, Inc.
Tested
Placebo (biological), mRNA-1345 (biological), Afluria® Quadrivalent (biological), mRNA-1273.214 (biological)
Dates
Started 2022-04-01; completion 2024-11-08
Results posted
Yes

The main purposes of Part A of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine (Afluria® Quadrivalent); to evaluate the impact of coadministered influenza vaccine on the immune response to RSV-A; and to evaluate the impact of coadministered RSV vaccine on the immune response to influenza. The main purposes of Part B of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with mRNA-1273.214; to evaluate the effect of coadministered mRNA-1273.214 on the immune response to RSV-A; and to evaluate the effect of coadministered RSV vaccine on the immune response to…

From ClinicalTrials.gov, last updated 2025-12-30. Full record, eligibility and contacts (opens in a new tab)

Industry funding

ModernaTX, Inc. reported $2.0M in research payments for this study in 2025 (266 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Indago Research and Health Center Inc $718,718
  • Velocity Clinical Research Inc $213,449
  • Qcare Site Services Inc $148,675
  • Suncoast Research Associates LLC $116,397
  • Dolphin Medical Research $108,200
  • Suncoast Research Group LLC $99,810
  • Pharmaseek LLC $96,494
  • Del Sol Research Management LLC $74,773
  • Empire Clinical Research LLC $67,238
  • Floridian Clinical Research LLC $65,312
  • Teradan Clinical Trials LLC $64,162
  • New Phase Research and Development $45,256
  • Long Beach Clinical Trials LLC $34,485
  • Trial Management Associates LLC $32,494
  • Revival Research $27,801
  • Wr Mccr LLC $24,397
  • Ark Clinical Research LLC $19,657
  • Chase Medical Research LLC $13,555
  • Elligo Health Research Inc $10,273
  • Qcare Site Services $5,560
  • Ima Clinical Research PC $5,500
  • Lsb Research Group LLC $3,275

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.